DYAI Covid-19 Vaccine for the African Continent

28 ก.ค. 2021

Dyadic International signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium.

The Rubic Consortium is made up of promoters of the project representing public health, medical, academia, vaccine technology, technology transfer and economics sectors.

Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement.
Provides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials.
Establishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100.
Intends to reduce African dependence on foreign vaccine suppliers.
Combined with previous C1 COVID-19 vaccine collaborations in India and South Korea (including Southeast Asia), this agreement further supports the potential for C1 produced COVID-19 immunization coverage to more than 40% of the world’s population. (rubicconsortium.co.za)

Now what is the potential for DYAI???

The 52 Week Range is 3.1500 - 9.1900
Now the price is 3.89usd, so close to the lower end.
The market cap is only 107Mil

The biggest owner, 4.744%, is BlackRock Inc. which reported on 5/7/2021 1,307,205 shares on DYAI for a market value of 7.18Mil.
if we make an average, Blackrock bought DYAI at 5.5usd per share. and i don`t think it will sell for less, especially with new COVID-19 vaccine coming.

The second important owner is Vanguard Group Inc., which has 709,698 shares at a market value of 4.44Mil. they bought DYAI at 6.25usd and didn`t panic sell when the stock went to 2.5usd!

My short term price target is 6.5usd, but on the long run, depending on the efficacy of the vaccine, this company can worth Billions!
Just remember MRNA before it made 25X!